ICLE 2022 | Cell avidity as a predictor of T-cell efficacy
Yotam Bar-Ephraim
• 1 Apr 2022
Yotam Bar-Ephraim, PhD, LUMICKS, Amsterdam, The Netherlands, comments on research assessing how transgenic T-cell receptors and T-cell avidity affect immunotherapy responses. The addition of two costimulatory receptors increased cell avidity and hence T-cell cytotoxicity, and removing the signaling domain enhanced valency, demonstrating the important of cell avidity. T-cell clones specific for G12D KRAS mutations were additionally isolated from a sample of tumor infiltrating lymphocytes and cell avidity was found to be a more accurate indicator of T-cell efficacy than T-cell receptor affinity and persistence. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
